ANL 15.53 Increased By ▲ 15.53 (0%)
ASC 13.14 Increased By ▲ 13.14 (0%)
ASL 17.85 Increased By ▲ 17.85 (0%)
BOP 8.33 Increased By ▲ 8.33 (0%)
BYCO 7.35 Increased By ▲ 7.35 (0%)
FCCL 17.52 Increased By ▲ 17.52 (0%)
FFBL 22.53 Increased By ▲ 22.53 (0%)
FFL 12.56 Increased By ▲ 12.56 (0%)
FNEL 7.50 Increased By ▲ 7.50 (0%)
GGGL 17.21 Increased By ▲ 17.21 (0%)
GGL 30.50 Increased By ▲ 0.50 (1.67%)
HUMNL 6.95 Increased By ▲ 0.30 (4.51%)
JSCL 19.40 Increased By ▲ 19.40 (0%)
KAPCO 27.31 Increased By ▲ 27.31 (0%)
KEL 3.36 Increased By ▲ 3.36 (0%)
MDTL 2.20 Increased By ▲ 2.20 (0%)
MLCF 35.00 Increased By ▲ 0.75 (2.19%)
NETSOL 104.99 Increased By ▲ 104.99 (0%)
PACE 4.12 Increased By ▲ 4.12 (0%)
PAEL 26.60 Increased By ▲ 26.60 (0%)
PIBTL 8.08 Increased By ▲ 8.08 (0%)
POWER 7.25 Increased By ▲ 7.25 (0%)
PRL 16.10 Increased By ▲ 0.30 (1.9%)
PTC 9.06 Increased By ▲ 9.06 (0%)
SILK 1.42 Increased By ▲ 1.42 (0%)
SNGP 39.74 Increased By ▲ 39.74 (0%)
TELE 16.61 Increased By ▲ 16.61 (0%)
TRG 123.46 Increased By ▲ 123.46 (0%)
UNITY 29.43 Increased By ▲ 29.43 (0%)
WTL 2.29 Increased By ▲ 2.29 (0%)
BR100 4,760 Increased By ▲ 116.8 (2.52%)
BR30 20,622 Increased By ▲ 327.01 (1.61%)
KSE100 45,851 Increased By ▲ 546.91 (1.21%)
KSE30 17,940 Increased By ▲ 231.5 (1.31%)
Business & Finance

AstraZeneca/Oxford vaccine more effective with longer dose gap: study

  • The study confirmed the Anglo-Swedish drugmaker's findings from earlier this month that showed the vaccine had 76% efficacy against symptomatic coronavirus infection for three months after the first dose.
  • Efficacy was found to be at 81% with the longer interval of 12 weeks between the first and second dose, compared with 55% efficacy up to the six-week gap.
19 Feb 2021

AstraZeneca and Oxford University's COVID-19 vaccine is more effective when its second dose is given three months after the first, instead of six weeks, a peer-reviewed study published in The Lancet medical journal showed on Friday.

The study confirmed the Anglo-Swedish drugmaker's findings from earlier this month that showed the vaccine had 76% efficacy against symptomatic coronavirus infection for three months after the first dose.

Efficacy was found to be at 81% with the longer interval of 12 weeks between the first and second dose, compared with 55% efficacy up to the six-week gap, according to the Lancet study, which backs British and WHO recommendations for longer intervals.

Faced with a resurgence in infections and new, highly transmissible variants of the virus, many countries are hoping to broaden immunization by giving some protection to as many people as possible with a first dose, while delaying subsequent shots.

Comments

Comments are closed.